Analysts forecast that Kala Pharmaceuticals Inc (NASDAQ:KALA) will report sales of $2.62 million for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Kala Pharmaceuticals’ earnings. The highest sales estimate is $3.25 million and the lowest is $2.00 million. The business is scheduled to report its next earnings report on Thursday, August 8th.

On average, analysts expect that Kala Pharmaceuticals will report full-year sales of $13.66 million for the current year, with estimates ranging from $7.00 million to $20.00 million. For the next financial year, analysts anticipate that the firm will report sales of $75.11 million, with estimates ranging from $38.90 million to $110.00 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for Kala Pharmaceuticals.

Kala Pharmaceuticals (NASDAQ:KALA) last posted its earnings results on Thursday, May 9th. The company reported ($0.75) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.75). The firm had revenue of $1.39 million for the quarter, compared to analyst estimates of $0.96 million.

A number of research firms have recently weighed in on KALA. Zacks Investment Research downgraded Kala Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 5th. BidaskClub raised Kala Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Jefferies Financial Group began coverage on Kala Pharmaceuticals in a report on Thursday, March 14th. They set a “buy” rating and a $15.00 target price for the company. Finally, Oppenheimer began coverage on Kala Pharmaceuticals in a report on Wednesday, April 24th. They set an “outperform” rating and a $11.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $19.21.

Shares of KALA traded up $0.06 during midday trading on Wednesday, reaching $5.94. 232,401 shares of the stock were exchanged, compared to its average volume of 212,185. Kala Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $17.33. The company has a debt-to-equity ratio of 0.67, a quick ratio of 10.17 and a current ratio of 10.41. The company has a market capitalization of $201.27 million, a P/E ratio of -2.40 and a beta of 1.64.

A number of hedge funds have recently bought and sold shares of KALA. RA Capital Management LLC raised its stake in Kala Pharmaceuticals by 114.7% in the fourth quarter. RA Capital Management LLC now owns 4,537,478 shares of the company’s stock valued at $22,188,000 after purchasing an additional 2,424,242 shares in the last quarter. Athyrium Capital Management LP acquired a new position in Kala Pharmaceuticals in the fourth quarter valued at about $6,520,000. Sofinnova Investments Inc. raised its stake in Kala Pharmaceuticals by 365.8% in the fourth quarter. Sofinnova Investments Inc. now owns 445,516 shares of the company’s stock valued at $2,178,000 after purchasing an additional 349,861 shares in the last quarter. BlackRock Inc. raised its stake in Kala Pharmaceuticals by 29.2% in the fourth quarter. BlackRock Inc. now owns 1,427,672 shares of the company’s stock valued at $6,980,000 after purchasing an additional 322,311 shares in the last quarter. Finally, Fosun International Ltd acquired a new position in Kala Pharmaceuticals in the fourth quarter valued at about $1,208,000. 67.92% of the stock is owned by institutional investors and hedge funds.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

See Also: What is the Book Value of a Share?

Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.